Key facts
- Embolx’s last known valuation is $37.6M (Jul 2021).
- It has raised $16.5M across 3 recorded rounds; the latest was Seed Round ($1.6M) in Oct 2022.
- Notable investors include US National Science Foundation, MedTech Innovator, Keiretsu Forum, Band of Angels, VI Ventures — 14 tracked in total.
- Embolx has filed 5 Form Ds with the SEC since 2014, most recently Nov 2022 ($1.6M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Embolx
Funding rounds
3 roundsAbout Embolx
Developer of medical devices designed for arterial embolization procedures. The company offers advanced microcatheters that leverage both high- and low-pressure technologies, enabling interventional radiologists and healthcare providers to perform targeted embolization with enhanced efficiency, ease of use, and extended shelf life, thereby supporting improved patient outcomes in the medical device market.
- Sector
- Healthcare
- HQ
- Sunnyvale, CA, United States
- Founded
- 2013
- Employees
- 16
- Website
- embolx.com/
- Ownership
- Privately Held (backing)
Embolx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Embolx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Embolx in its N-PORT filings yet. We sweep new filings monthly.